Pharma Mar, S.A.
Research Pharma Mar, S.A. (PHM.MC) on Bullrun: market cap EUR 1.23B, P/E 22.2, dividend yield 1.5%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPHM.MC
- ExchangeMC
- CountrySpain
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 1.23B
- P/E22.2
- Dividend yield1.5%
- Financial periodQ2 2026
- RevenueEUR 49.61M
- Net income-EUR 972.00K
- Free cash flowEUR 1.06M
- Gross margin90.5%
Valuation Snapshot
latest market cap is EUR 1.23B; P/E is 22.2; dividend yield is 1.5%.
Peer valuation comparison
Latest P/E is 22.17x versus a Healthcare sector median of 24.64x (10.0% below).
Latest dividend yield is 1.49% versus a Healthcare sector median of 1.83% (18.4% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-04 | EUR 1.23B | 22.2 | 1.4% | 1 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1 EUR, yield 1.5%.
About Pharma Mar, S.A.
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer;
ETFs that hold Pharma Mar, S.A.
Pharma Mar, S.A. is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| L&G Global Thematic ESG Exclusions UCITS ETF USD Accumulating | 1.04% | 0.60% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Pharma Mar, S.A.'s market cap?
Pharma Mar, S.A.'s market capitalization is EUR 1.23B.
What is Pharma Mar, S.A.'s P/E ratio?
Pharma Mar, S.A.'s price-to-earnings (P/E) ratio is 22.2.
Does Pharma Mar, S.A. pay a dividend?
Pharma Mar, S.A. has a dividend yield of 1.5%.
What does Pharma Mar, S.A. do?
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments.